Clinical utility of plasma A β42/40 ratio by LC-MS/MS in Alzheimer’s disease assessment

ConclusionHigh-throughput plasma Aβ42/40 LC-MS/MS assays can help identify patients with low likelihood of AD pathology, which can reduce PET evaluations, allowing for cost savings.

Source: Frontiers in Neurology - March 25, 2024 Category: Neurology Source Type: research